Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Equity Average (2020 - 2025)

Goldenwell Biotech's Equity Average history spans 6 years, with the latest figure at -$90830.5 for Q3 2025.

  • For Q3 2025, Equity Average fell 887.6% year-over-year to -$90830.5; the TTM value through Sep 2025 reached -$90830.5, down 887.6%, while the annual FY2024 figure was $18741.0, 86.91% down from the prior year.
  • Equity Average reached -$90830.5 in Q3 2025 per GWLL's latest filing, down from -$84228.0 in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $360802.0 in Q2 2021 to a low of -$90830.5 in Q3 2025.
  • Average Equity Average over 5 years is $144219.9, with a median of $154470.5 recorded in 2023.
  • Peak YoY movement for Equity Average: skyrocketed 43.46% in 2021, then crashed 887.6% in 2025.
  • A 5-year view of Equity Average shows it stood at $316483.5 in 2021, then tumbled by 30.71% to $219284.0 in 2022, then plummeted by 56.62% to $95122.5 in 2023, then plummeted by 114.72% to -$14001.0 in 2024, then plummeted by 548.74% to -$90830.5 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Equity Average are -$90830.5 (Q3 2025), -$84228.0 (Q2 2025), and -$64429.5 (Q1 2025).